This study is exploring new treatments for advanced renal cell carcinoma (RCC), a type of kidney cancer. One medicine being studied is belzutifan, a targeted therapy. Targeted therapy works by focusing on specific cancer cells to stop them from growing and spreading. Researchers want to see if adding another targeted therapy called zanzalintinib helps more people compared to using belzutifan alone.

The study will compare two groups: one will get both belzutifan and zanzalintinib, and the other will get belzutifan and a placebo (a harmless pill that looks like the medicine). The goal is to find out if the combination helps people live longer without their cancer getting worse.

• The study involves multiple visits for treatment and monitoring.
• Participants should have a confirmed diagnosis of advanced RCC and meet specific health criteria.
• There are potential risks and side effects, such as heart issues or breathing problems, which will be monitored.